New Yaz Lawsuit Complaint Filed
08/08/2012–A Yaz Lawsuit was filed by Kathrine Ruffin because of the adverse reaction(s) suffered by Plaintiff after her use of the contraceptive Yaz/Yasmin/Ocella. The Plaintiff was diagnosed with a pulmonary embolism and deep vein thrombosis approximately one year after she started taking Yaz/Yasmin/Ocella as per her doctor’s direction.
If you took Yaz or Yasmin and suffered an side effect related to blood clots and would like more information on filing a Yaz Lawsuit or Yasmin Lawsuit please contact us at 1-800-611-7080
The Plaintiff will likely have ongoing medical expenses and will need further medical care as a result of her injuries. The Yaz Lawsuit and Yasmin Lawsuit are both part of a Multi District Litigation currently underway in Illinois. Ocella is also included in the Yaz Multidistrict Litigation, often referred to as the Yaz Class Action Lawsuit however, Ocella was sold as a generic and could be effected by recent court rulings regarding the liability of Pharmaceutical Companies that make generic drugs.
The complaint alleges that even though the FDA approved the use of Yaz/Yasmin/Ocella in 2001, that Defendants (the manufacturers, designers, and marketers of Yaz/Yasmin/Ocella) knew of the high risk of injury that could be caused by use of Yaz/Yasmin/Ocella. The complaint points to a report issued by the British Medical Journal in 2002. This report recommended that alternative contraceptives be prescribed in lieu of Yaz/Yasmin/Ocella due to the 40 cases of venous thrombosis discovered in women taking Yasmin at that time. In 2003 another paper was published in the British Medical Journal that found five additional thrombosis cases thought to be attributed to Yasmin, including two deaths.
The complaint further alleges that Defendants knew or should have known of the risks associated with Yaz/Yasmin/Ocella. The complaint states that the FDA warned Defendants in 2003 and 2008 for misleading the public through the use of television ads which overstated the efficacy of Yasmin, Yaz and/or Ocella while minimizing mention of the serious risks associated with the drug. It was not until 2011 that Plaintiff knew or should have known of the risks of cardiac injury because that is when the warning labels for these contraceptives changed.
Many of the causes of action in the complaint involve allegations of fraud and/or concealment. Plaintiff asserts that the Defendants purposefully did not warn consumers or medical professionals of the serious risks associated with Yaz/Yasmin/Ocella solely for Defendants’ financial gain.
Posted in: Knock3
Leave a Reply
You must be logged in to post a comment.